Literature DB >> 1160970

Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer.

B R Henderson, V Gerkins, I Rosario, J Casagrande, M C Pike.   

Abstract

Demographic risk factors in sisters and daughters of 150 patients with breast cancer were compared to those of controls. Plasma hormone levels in 36 teen-age daughters of patients and 31 controls were also studied to ascertain whether an "abnormal" hormone pattern underlies these risk factors. The patients' sisters had, on the average, menarche four months earlier and first full-term pregnancy 12 months later than the controls. The patients' daughters did not show these differences -- apparently owing to low fertility in the patients with early menarche. The patients' daughters had higher 22d-day estradiol-plus-estrone levels than controls (24.4 vs. 19.1 ng per 100 ml, P less than 0.05). Sixth-day prolactin was also elevated (19.0 vs. 14.2 ng per 100 ml, P less than 0.05). About half the patients' daughters could clearly be distinguished from the controls' daughters by means of the sixth-day information on both estrogens and prolactin. Hypersecretion of these hormones may be important factors in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1160970     DOI: 10.1056/NEJM197510162931602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  16 in total

Review 1.  The international variation in breast cancer rates: an epidemiological assessment.

Authors:  B E Henderson; L Bernstein
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

2.  Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States).

Authors:  S E Hankinson; G A Colditz; D J Hunter; J E Manson; W C Willett; M J Stampfer; C Longcope; F E Speizer
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

Review 3.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

4.  Treatment of benign breast disease with bromocriptine.

Authors:  A Mussa; L Dogliotti
Journal:  J Endocrinol Invest       Date:  1979 Jan-Mar       Impact factor: 4.256

5.  Determination and properties of proteohormone receptors in malignant gynecological tumors with special reference to lactogen receptors in human breast cancer.

Authors:  H G Bohnet
Journal:  Arch Gynecol       Date:  1980

6.  Circulating prolactin levels and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

7.  Breast cancer in a male patient with prolactinoma.

Authors:  S Haga; O Watanabe; T Shimizu; T Iida; H Imamura; T Kajiwara; M Fujibayashi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

8.  Adult Physical Activity and Breast Cancer Risk in Women with a Family History of Breast Cancer.

Authors:  Alexandra J White; Dale P Sandler; Nicole M Niehoff; Hazel B Nichols; Shanshan Zhao
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-17       Impact factor: 4.254

Review 9.  Prolactin and breast cancer etiology: an epidemiologic perspective.

Authors:  Shelley S Tworoger; Susan E Hankinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

10.  Breast cancer in Greenland--selected epidemiological, clinical, and histological features.

Authors:  N H Nielsen; J P Hansen
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.